|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR1800020070 |
|
最近更新日期: Date of Last Refreshed on: |
2018-12-13 13:45:22 |
|
注册时间: Date of Registration: |
2018-12-13 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
九味镇心颗粒治疗广泛性焦虑症开放、多中心IV期临床试验 |
|
Public title: |
An open-label, multi-center, Phase IV clinical study of Jiuwei Zhenxin Granules in the treatment of generalized anxiety disorder |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
九味镇心颗粒治疗广泛性焦虑症开放、多中心IV期临床试验 |
|
Scientific title: |
An open-label, multi-center, Phase IV clinical study of Jiuwei Zhenxin Granules in the treatment of generalized anxiety disorder |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吉恋英 |
研究负责人: |
李静 |
|
Applicant: |
Ji Lianying |
Study leader: |
Li Jing |
|
申请注册联系人电话: Applicant telephone: |
+86 010 62622266-898 |
研究负责人电话: Study leader's telephone: |
+86 139 0818 6821 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jily@beilu.com.cn |
研究负责人电子邮件: Study leader's E-mail: |
joana028@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区西直门北大街32号枫蓝国际A座7层 |
研究负责人通讯地址: |
四川省成都市武侯区电信南街28号 |
|
Applicant address: |
7th Floor, Block A, Maples International office, 32 Xizhimen Street North, Hai'dian District, Beijing, China |
Study leader's address: |
28 Dianxin Street South, Chengdu, Sichuan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
100082 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
北京北陆药业股份有限公司 |
||
|
Applicant's institution: |
Beijing Beilu Pharmaceutical Co.,Ltd. |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2008年临床试验(上市药)审13号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics committee of West China School of Medicine/West China Hospital of Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2009-03-06 00:00:00 |
||
|
伦理委员会联系人: |
李娜 |
||
|
Contact Name of the ethic committee: |
Li Na |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
37 Guoxue Lane, Chengdu, Sichuan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China School of Medicine/West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Lane, Chengdu, Sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京北陆药业股份有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing BeiLu Pharmaceutical Co.,Ltd. |
||||||||||||||||||||||
|
Target disease: |
generalized anxiety disorder |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
IV期临床试验 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
评价九味镇心颗粒上市后,在广泛使用条件下,治疗广泛性焦虑症的疗效和不良反应,并积累改进给药方案的科学数据和经验。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and adverse events of Jiuwei Zhenxin Keli in the treatment of generalized anxiety disorder under the conditions of wide use after marketing, and to accumulate and improve scientific data and experience about dosing regimen. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、符合中医辨证与西医辨病相结合的双重诊断标准。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. The standards of syndrome differentiation in Traditional Chinese Medicine and disease differentiation in Western Medicine are met: |
||||||||||||||||||||||
|
排除标准: |
1、具有严重心、肝、肾疾患、 甲状腺功能亢进或严重器质性疾病者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. The patient who suffers from serious cardiac, hepatic and renal diseases, hyperthyroidism or serious organic diseases; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2010-12-01 00:00:00至 To 2016-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2010-12-01 00:00:00 至 To 2016-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
N/A |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan (www.medresman.org) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan (www.medresman.org) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |